News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,941 Results
Type
Article (87419)
Company Profile (739)
Press Release (770765)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232802)
Career Advice (4143)
Deals (39873)
Drug Delivery (144)
Drug Development (91177)
Employer Resources (205)
FDA (18254)
Job Trends (17422)
News (396887)
Policy (39843)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (121)
Alliances (56795)
ALS (153)
Alzheimer's disease (1752)
Antibody-drug conjugate (ADC) (321)
Approvals (18376)
Artificial intelligence (470)
Autoimmune disease (155)
Automation (31)
Bankruptcy (402)
Best Places to Work (12525)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (150)
Brain cancer (53)
Breast cancer (559)
Cancer (4352)
Cardiovascular disease (302)
Career advice (3568)
Career pathing (41)
CAR-T (289)
CDC (36)
Celiac Disease (1)
Cell therapy (763)
Cervical cancer (29)
Clinical research (76181)
Collaboration (1607)
Company closure (4)
Compensation (996)
Complete response letters (64)
COVID-19 (2927)
CRISPR (85)
C-suite (736)
Cystic fibrosis (143)
Data (5479)
Decentralized trials (2)
Denatured (73)
Depression (114)
Diabetes (345)
Diagnostics (6982)
Digital health (25)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (252)
Drug pricing (161)
Drug shortages (19)
Duchenne muscular dystrophy (198)
Earnings (98429)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132838)
Executive appointments (826)
FDA (20683)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1276)
Gene editing (183)
Generative AI (46)
Gene therapy (601)
GLP-1 (939)
Government (5323)
Grass and pollen (4)
Guidances (317)
Healthcare (20778)
HIV (43)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (58)
Indications (81)
Infectious disease (3146)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (95)
Intellectual property (198)
Interviews (816)
IPO (17808)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10091)
Liver cancer (89)
Longevity (13)
Lung cancer (592)
Lymphoma (336)
Machine learning (41)
Management (66)
Manufacturing (716)
MASH (159)
Medical device (14440)
Medtech (14471)
Mergers & acquisitions (22744)
Metabolic disorders (1071)
Multiple sclerosis (149)
NASH (22)
Neurodegenerative disease (330)
Neuropsychiatric disorders (81)
Neuroscience (2899)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5079)
Now hiring (65)
Obesity (526)
Opinion (325)
Ovarian cancer (151)
Pain (155)
Pancreatic cancer (172)
Parkinson's disease (263)
Partnered (33)
Patents (394)
Patient recruitment (417)
Peanut (56)
People (66286)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23609)
Phase 2 (33136)
Phase 3 (24868)
Pipeline (4397)
Policy (283)
Postmarket research (3544)
Preclinical (10589)
Press Release (72)
Prostate cancer (208)
Psychedelics (51)
Radiopharmaceuticals (279)
Rare diseases (796)
Real estate (7423)
Recruiting (80)
Regulatory (28256)
Reports (64)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (63)
Schizophrenia (139)
Series A (224)
Series B (160)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4323)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (76)
The Weekly (122)
Vaccines (998)
Venture capital (91)
Weight loss (344)
Women's health (73)
Worklife (22)
Date
Last 7 days (482)
Last 30 days (1667)
Last 365 days (25668)
2026 (2397)
2025 (25999)
2024 (34227)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (86)
Alaska (6)
Arizona (291)
Arkansas (8)
Asia (51146)
Australia (9002)
California (9834)
Canada (2550)
China (1060)
Colorado (315)
Connecticut (396)
Delaware (316)
Europe (117003)
Florida (1275)
Georgia (261)
Hawaii (4)
Idaho (65)
Illinois (681)
India (56)
Indiana (452)
Iowa (21)
Japan (351)
Kansas (133)
Kentucky (27)
Louisiana (16)
Maine (60)
Maryland (1264)
Massachusetts (7367)
Michigan (254)
Minnesota (460)
Mississippi (5)
Missouri (83)
Montana (28)
Nebraska (29)
Nevada (107)
New Hampshire (58)
New Jersey (2605)
New Mexico (29)
New York (2570)
North Carolina (1421)
North Dakota (9)
Northern California (4819)
Ohio (266)
Oklahoma (18)
Oregon (51)
Pennsylvania (1891)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (15)
South Dakota (1)
Southern California (3805)
Tennessee (61)
Texas (1384)
United States (34295)
Utah (216)
Vermont (1)
Virginia (170)
Washington D.C. (54)
Washington State (858)
West Virginia (2)
Wisconsin (85)
858,941 Results for "q32 bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Q32 Bio Joins Russell 3000® Index
Q32 Bio Inc. today announced that the company is joining the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.
July 1, 2024
·
6 min read
Deals
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Q32 Bio Inc. (NASDAQ: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the completion of its previously announced merger with Homology Medicines, Inc. (“Homology”).
March 25, 2024
·
9 min read
Business
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced the appointment of Lee Kalowski as President and Chief Financial Officer.
April 3, 2024
·
6 min read
Business
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, reported financial results for the quarter ended March 31, 2024 and provided recent corporate updates.
May 9, 2024
·
11 min read
Deals
Q32 Bio and Homology Medicines Announce Merger Agreement
Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
November 16, 2023
·
17 min read
Biotech Bay
Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced that it will regain full development and commercial rights to bempikibart from Amgen.
November 16, 2023
·
8 min read
Business
Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer.
October 24, 2023
·
3 min read
Mergers & acquisitions
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
Regulatory documents show how 89bio’s board pushed Roche hard for a deal valued at $20 per share in upfront and milestone payments.
October 2, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
January 27, 2026
·
2 min read
Press Releases
FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference
January 8, 2026
·
1 min read
1 of 85,895
Next
